Zymeworks
ZYME
26.53
+0.88
+3.43%
Zymeworks
US · ZYME
#2828 by market cap
Listed 2017
26.53
+0.88
+3.43%
Live - 5344 symbols - heartbeat 457s ago
· 2026-10-08 05:35
Pre-market
26.48
-0.19%
After-hours
25.99
-2.04%
- Market cap
- 1.90B
- P/E (TTM)i
- -13.13
- P/Bi
- 23.69
- EPSi
- -1.08
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on ZYME?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 98.15% -0.09pp
- Institutions
- 252 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund52.96%
Mutual Fund31.90%
VC/PE Fund7.51%
Public Company4.83%
Individual/Insider1.32%
Private Company0.52%
Government Pension Fund0.43%
Other0.53%
Top holders as of 2026-06-30
EcoR1 Capital, LLC
32.37% · 22.97M sh
Rubric Capital Management LP
9.86% · 7.00M sh
BlackRock
5.99% · 4.25M sh
Perceptive Advisors LLC
5.89% · 4.18M sh
BVF Partners L.P.
5.14% · 3.65M sh
Morgan Stanley
3.03% · 2.15M sh
Vanguard Capital Management, LLC
2.31% · 1.64M sh
BNPP Asset Management Holding
2.30% · 1.63M sh
Assenagon Asset Management S.A.
1.76% · 1.25M sh
Nextech Invest Ltd.
1.57% · 1.11M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 3 sells
| Name | Role | Stake |
|---|---|---|
| EcoR1 Capital, LLC | -- | 32.37% |
| Gregory Ciongoli | Director | 0.70% |
| Kenneth Galbraith | Chairperson & CEO | 0.32% |
| Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | 0.19% |
| Paul Moore | Chief Scientific Officer | 0.07% |
| Jeffrey T. Smith | -- | 0.04% |
| Troy Cox | Independent Director | 0.01% |
| Leone Patterson | CFO, EVP & Chief Business Officer | 0.00% |
| Brian Cherry | Director | -- |
| Nancy Davidson | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-05 | Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | Other Acquisition | +939 | $22.22 |
| 2026-05-12 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +119,000 | -- |
| 2026-05-12 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +178,000 | $24.57 |
| 2026-05-12 | Paul Schneider | Executive Vice President | Initial Statement of Beneficial | 0 | -- |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Other Derivative Acquisition | +47,000 | -- |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Other Derivative Acquisition | +70,000 | $27.35 |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Other Derivative Acquisition | +76,000 | -- |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-08 | Scott Platshon | Director | Other Derivative Acquisition | +47,000 | -- |
| 2026-04-08 | Scott Platshon | Director | Other Derivative Acquisition | +70,000 | $27.35 |
| 2026-04-08 | Scott Platshon | Director | Other Derivative Acquisition | +76,000 | -- |
| 2026-04-08 | Scott Platshon | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-05 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +169,000 | -- |
| 2026-04-05 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +178,000 | $25.84 |
| 2026-03-31 | Kristin Stafford | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-01-31 | Sabeen Mekan | Senior Vice President of Clinical Development | Initial Statement of Beneficial | 0 | -- |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Derivative Exercise and Sale | -30,424 | $22.67 |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +144,000 | -- |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +216,000 | $23.16 |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +222,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:35:07 · For reference only, not investment advice and not tailored to your situation.